Rise in plasma concentration of aldosterone during long-term angiotensin II suppression
- PMID: 7035596
- DOI: 10.1677/joe.0.0910457
Rise in plasma concentration of aldosterone during long-term angiotensin II suppression
Abstract
The plasma concentration of aldosterone was followed in seven hypertensive patients before and during long-term angiotensin II suppression with the orally active angiotensin-I-converting-enzyme inhibitor, captopril. The plasma concentration of aldosterone decreased initially from 74 to 21 pg/ml (P less than 0.05) after 1 month of administration of captopril. Thereafter the plasma concentration of aldosterone began to rise and after 1 year reached a level of 165 pg/ml. During long-term captopril therapy the plasma renin activity remained increased and the plasma angiotensin II concentration suppressed. The mechanism responsible for the late rise of the plasma concentration of aldosterone during long-term angiotensin II suppression with captopril remains to be elucidated. A sizeable and lasting hypotensive effect was observed in all patients.
Similar articles
-
Increase in plasma aldosterone during prolonged captopril treatment.Am J Cardiol. 1982 Apr 21;49(6):1561-3. doi: 10.1016/0002-9149(82)90390-3. Am J Cardiol. 1982. PMID: 7041598
-
Captopril in the long-term treatment of essential hypertension: changes in the renin-angiotensin-aldosterone system.Am J Cardiol. 1982 Apr 21;49(6):1555-7. doi: 10.1016/0002-9149(82)90388-5. Am J Cardiol. 1982. PMID: 6803566
-
Captopril in primary hypertension. Effects related to the renin-angiotensin-aldosterone and kallikrein-kinin systems.Acta Med Scand Suppl. 1981;646:98-105. Acta Med Scand Suppl. 1981. PMID: 7018190
-
Captopril in clinical hypertension. Changes in components of renin-angiotensin system and in body composition in relation to fall in blood pressure with a note on measurement of angiotensin II during converting enzyme inhibition.Br Heart J. 1980 Sep;44(3):290-6. doi: 10.1136/hrt.44.3.290. Br Heart J. 1980. PMID: 7000102 Free PMC article.
-
Captopril in the treatment of hypertension.Acta Clin Belg. 1982;37(3):164-84. doi: 10.1080/22953337.1982.11718860. Acta Clin Belg. 1982. PMID: 6214916 Review. No abstract available.
Cited by
-
Aldosterone, parathyroid hormone, and the use of renin-angiotensin-aldosterone system inhibitors: the multi-ethnic study of atherosclerosis.J Clin Endocrinol Metab. 2015 Feb;100(2):490-9. doi: 10.1210/jc.2014-3949. Epub 2014 Nov 20. J Clin Endocrinol Metab. 2015. PMID: 25412416 Free PMC article.
-
Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome.Clin Exp Nephrol. 2010 Aug;14(4):303-14. doi: 10.1007/s10157-010-0298-8. Epub 2010 Jun 9. Clin Exp Nephrol. 2010. PMID: 20533072 Review.
-
Aldosterone breakthrough from a pharmacological perspective.Hypertens Res. 2023 May;46(5):1350. doi: 10.1038/s41440-023-01204-2. Epub 2023 Feb 21. Hypertens Res. 2023. PMID: 36810620 No abstract available.
-
Angiotensin-Converting Enzyme Inhibition and Parathyroid Hormone Secretion.Int J Endocrinol. 2017;2017:4138783. doi: 10.1155/2017/4138783. Epub 2017 Jul 20. Int J Endocrinol. 2017. PMID: 28808443 Free PMC article.
-
The use of aldosterone receptor blockers in the treatment of hypertension.J Clin Hypertens (Greenwich). 2004 Nov;6(11):632-5. doi: 10.1111/j.1524-6175.2004.03057.x. J Clin Hypertens (Greenwich). 2004. PMID: 15538096 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical